Net Loss Per Share

3 Months Ended

Mar. 31, 2026

Net loss per share

The following table summarizes potentially dilutive securities excluded from the computation of diluted net loss per share calculations because they would have been antidilutive (in millions):


	As of March 31,
	2026	2025
Common stock options issued and outstanding	18.3	18.0
Restricted stock units issued	4.6	4.3
Employee stock purchase plan shares	0.5	0.3
Total potentially dilutive securities	23.4	22.6

We have also excluded from the calculation at March 31, 2025 the effect of Gilead’s right to purchase additional shares of our common stock, which expired in July 2025, as these rights had no intrinsic value.